| Literature DB >> 36102402 |
Gabriella Vieira Carneiro1, Fabiana Sodré de Oliveira1, Leandro Alves Pereira1, Érica Rodrigues Mariano de Almeida Rezende1, Luciana Carneiro Pereira Gonçalves1, Vivian Mara Gonçalves de Oliveira Azevedo1.
Abstract
OBJECTIVE: To analyze the association between phenotypic and genotypic characteristics and disease severity in individuals with cystic fibrosis treated at a reference center in Minas Gerais, Brazil.Entities:
Mesh:
Year: 2022 PMID: 36102402 PMCID: PMC9462412 DOI: 10.1590/1984-0462/2023/41/2021286
Source DB: PubMed Journal: Rev Paul Pediatr ISSN: 0103-0582
Clinical and laboratory characteristics*.
| Clinical and laboratory characteristics | n (%) | Clinical and laboratory characteristics | n (%) | ||
|---|---|---|---|---|---|
| Gender | Female | 25 (50) |
| ||
| Male | 25 (50) | Meconium ileus | 4 (8) | ||
| Ethnicity | Caucasian | 37 (74) | Pancreatic insufficiency | 45 (90) | |
| Not Caucasian | 13 (26) | Hepatic steatosis | 12 (24) | ||
| Age group | Infant | 3 (6) | Hepatic fibrosis | 1 (2) | |
| Preschool | 11 (22) | Gallstones | 6 (12) | ||
| Schoolchildren | 10 (20) | Gastritis | 12 (24) | ||
| Adolescent | 15 (30) | Splenomegaly | 2 (4) | ||
| Adult | 11 (22) | Hepatomegaly | 2 (4) | ||
|
| Nutritional status | Appropriate | 34 (68) | ||
| Positive neonatal screening | 28 (56) | Underweight/thin | 23 (26) | ||
| Age at diagnosis | Up to 1 month | 22 (44) | Overweight | 3 (6) | |
| 1 month to 2 years | 18 (36) |
| |||
| 2 to 10 years | 6 (12) | Kidney stones | 3 (6) | ||
| >10 years | 4 (8) | Diabetes | 3 (6) | ||
|
|
| ||||
| Death | 4 (8) | Pancreatic enzyme | 45 (90) | ||
| Shwachman-Kulczycki score classification | Severe | 1 (2) | Antibiotic | 26 (52) | |
| Moderate | 5 (10) | Inhaled glucocorticoids | 26 (52) | ||
| Mild | 3 (6) | Mucolytics | 40 (80) | ||
| Good | 18 (36) | Corticosteroid bronchodilator | 28 (56) | ||
| Excellent | 23 (46) | Antiulcer agents | 30 (60) | ||
|
| Multivitamin supplement | 48 (96) | |||
| Colonization classification | Lack of colonization | 19 (38) | Ursodeoxycholic acid | 9 (18) | |
| Intermittent colonization | 13 (26) | Insulin | 3 (6) | ||
| Chronic colonization | 18 (36) | Supervised physiotherapy | 19 (38) | ||
| Pathogen (colonization) |
| 7 (14) | Unsupervised airway clearance therapy | 20 (40) | |
|
| 20 (40) | Unsupervised physical activity | 25 (50) | ||
|
| 4 (8) |
| |||
| No colonization | 19 (38) | Hospitalized in the previous year | 14 (28) | ||
| Respiratory symptomatology (last visit) | Asymptomatic | 9 (18) | Number of hospitalizations | 1 | 4 (8) |
| Typical symptoms | 23 (46) | 2 | 7 (14) | ||
| Mildly exacerbated symptoms | 11 (22) | ≥3 | 3 (6) | ||
| Moderately exacerbated symptoms | 5 (10) | ||||
| Severely exacerbated symptoms | 2 (4) | ||||
| Hemoptysis | 2 (4) | ||||
| Sinusitis | 12 (24) | ||||
| Nasal polyps | 21 (42) | ||||
*Phenotype.
Prevalence of mutations in the Cystic Fibrosis Transmembrane Conductance Regulator gene and its functional classes.
| Patients (%) | Allele 1 mutation | Allele 2 mutation | ||||
|---|---|---|---|---|---|---|
| Traditional nomenclature | Current nomenclature | CF allele 1 mutation | Traditional nomenclature | Current nomenclature | CF allele 2 mutation | |
| 15 (30) | DeltaF508 | c.1521_1523delCTT | II | DeltaF508 | c.1521_1523delCTT | II |
| 1 (2) | No nomenclature | c.1486delT | NC | DeltaF508 | c.1521_1523delCTT | II |
| 1 (2) | G542X | c.1624G>T | I | V317E | c.950 T>A | NC |
| 2 (4) | 5T | c.1210-12T[5] | V | Absence of mutation | Absence of mutation | Absence of mutation |
| 2 (4) | S4X | c.11C>A | I | S4X | c.11C>A | I |
| 1 (2) | R334W | c.1000C>T | IV | R1162X | c.3484 C>T | I |
| 1 (2) | G542X | c.1624G>T | I | DeltaF508 | c.1521_1523delCTT | II |
| 1 (2) | 2184insA | c.2052_2053insA | I | S4X | c.11C>A | I |
| 1 (2) | S589N | c.1766G>A | III | DeltaF508 | c.1521_1523delCTT | II |
| 5 (10) | S4X | c.11C>A | I | DeltaF508 | c.1521_1523delCTT | II |
| 2 (4) | S4X | c.11C>A | I | G542X | c.1624G>T | I |
| 1 (2) | G85E | c.254 G>A | II | R334W | c.1000C>T | IV |
| 1 (2) | Exclusion of exon 2/CFTRdele2 | c. (53+1_54-1) _ (164+1_165-1) del | I | DeltaF508 | c.1521_1523delCTT | II |
| 3 (6) | S4X | c.11C>A | I | R1162X | c.3484 C>T | I |
| 1 (2) | G576A | c.1727 G>C | V | R668C | c.2002 C>T | III |
| 1 (2) | R334W | c.1000C>T | IV | W1282X | c.3846G>A | I |
| 1 (2) | 1717-1G>A | c.1585-1 G>A | I | DeltaF508 | c.1521_1523delCTT | II |
| 1 (2) | No nomenclature | c.1505T>G | NC | Absence of mutation | Absence of mutation | Absence of mutation |
| 1 (2) | S466X (TAG) | c.1397 C>G | I | DeltaF508 | c.1521_1523delCTT | II |
| 2 (4) | S4X | c.11C>A | I | 3272-26A>G | c.3140-26A>G | V |
| 1 (2) | A559T | c.1675 G>AT | II | DeltaF508 | c.1521_1523delCTT | II |
| 1 (2) | 711+1G>T | c.579+1G>T | I | DeltaF508 | c.1521_1523delCTT | II |
| 1 (2) | S4X | c.11C>A | I | I507del | c.1519_1521delAT | II |
| 1 (2) | S549R (T->G) | c.1647T>G | III | G542X | c.1624G>T | I |
| 1 (2) | L206W | c.617T>G | IV | DeltaF508 | c.1521_1523delCTT | II |
| 1 (2) | R851X | c.2551C>T | NC | DeltaF508 | c.1521_1523delCTT | II |
FC: functional classification; NC: no classification; HGVS: Human Genome Variation Society.
Association between phenotype and disease severity.
| Characteristics | Disease severity | p-value | |
|---|---|---|---|
| Respiratory symptomatology | Typical | 85.9±9.3 | * |
| Exacerbated | 74.1±17.5 | 0.071 | |
| Colonization |
| 80.0±10.0 | * |
|
| 81.0±14.7 | 0.283 | |
|
| 61.2±19.3 | 0.007 | |
| No colonization | 87.3±8.7 | 0.237 | |
| Nutritional status | Appropriate | 86.9±6.4 | * |
| Underweight/thin | 65.3±16.7 | 0.036 | |
| Overweight | 93.3±2.8 | 0.597 | |
|
|
|
| |
| Age | -0.165 | 0.099 | |
*Reference values in the comparison by regression analysis.
Association between phenotype and death.
| Death | p-value | |||
|---|---|---|---|---|
| Yes | No | |||
| Age | n | 4 | 46 | 0.158* |
| Mean age (in years) | 18.45 | 10.54 | ||
| Age at | n | 4 | 46 | 0.016* |
| Mean age (in months) | 47.00 | 2.00 | ||
| Gender | Female | 3 | 22 | 0.608** |
| Male | 1 | 24 | ||
| Pancreatic insufficiency | Yes | 4 | 41 | 0.491** |
| No | 0 | 5 | ||
| Pathogen (colonization) |
| 1 | 6 | 0.024** |
|
| 1 | 19 | ||
|
| 2 | 2 | ||
| No colonization | 0 | 19 | ||
| Respiratory symptomatology | Exacerbated symptoms | 4 | 14 | 0.013** |
| Typical symptoms | 0 | 32 | ||
| Nutritional status | Appropriate | 0 | 34 | 0.017** |
| Underweight/thin | 4 | 9 | ||
| Overweight | 0 | 3 | ||
| Supervised physiotherapy | Yes | 1 | 18 | 0.654** |
| No | 3 | 28 | ||
| Unsupervised airway clearance therapy | Yes | 2 | 18 | 0.673** |
| No | 2 | 28 | ||
| Unsupervised physical activity | Yes | 2 | 23 | 1** |
| No | 2 | 23 | ||
| Hospitalization | Yes | 4 | 10 | 0.003** |
| No | 0 | 36 | ||
*Kruskal-Wallis test for median comparison; **Kruskal-Wallis test for contingency tables.